Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 14/20 | 0.67 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.43 |
| ▸ | GABRP | O00591 | 4/20 | 0.43 |
| ▸ | GABRD | O14764 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.43 |
| ▸ | GABRE | P78334 | 4/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14975008 | 0.84 | PRKCI (0.64) | PRKCIPRKCZ | |
| SCHEMBL14986568 | 0.80 | PRKCI (1.00) | PRKCI | |
| SCHEMBL14975459 | 0.78 | PRKCI (0.64) | PRKCIPRKCZ | |
| SCHEMBL14975453 | 0.78 | PRKCZ (0.61) | PRKCIPRKCZ | |
| SCHEMBL14977500 | 0.77 | PRKCI (0.61) | PRKCIPRKCZ | |
| SCHEMBL14976783 | 0.77 | PRKCI (0.61) | PRKCIPRKCZ | |
| SCHEMBL16203434 | 0.76 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL16203435 | 0.76 | PRKCI (1.00) | PRKCIPRKCZ | |
| SCHEMBL14986346 | 0.75 | PRKCI (0.48) | PRKCIGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14975626 | 0.75 | PRKCI (0.63) | PRKCIPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604994-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604994-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-3048106-A1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2016-07-27 | — | — | EP | disclosed |
| EP-2782917-B1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER REC TECH LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PRKCZ 5/4885GABRP 2972/4885 |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKX, PRKCQ, PRKACA | PRKCI 16/4885PRKCZ 15/4885GABRP 2452/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | PRKCI 16/4885PRKCZ 15/4885GABRP 2452/4885 |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PRKCZ 5/4885GABRP 2972/4885 |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PRKCZ 5/4885GABRP 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.